Significant Effect of Raloxifene on Bone in Hemodialysis Patients

authors:

avatar Pernille Ravn 1 , *

Department of Gynecology and Obstetrics, Gynecologic Endocrinology Unit, Odense University Hospital, Odense C, Denmark
International Journal of Endocrinology and Metabolism: Vol.10, issue 4; 636-637
published online: September 29, 2012
article type: Letter
received: May 8, 2012
revised: May 10, 2012
accepted: May 12, 2012
DOI: https://doi.org/10.5812/ijem.6251

how to cite: Ravn P. Significant Effect of Raloxifene on Bone in Hemodialysis Patients. Int J Endocrinol Metab. 2012;10(4): 636-637. https://doi.org/10.5812/ijem.6251.

References

  • 1.

    Saito O, Saito T, Asakura S, Akimoto T, Inoue M, Ando Y, et al. Effects of Raloxifene on Bone Metabolism in Hemodialysis Patients With Type 2 Diabetes. Int J Endocrinol Metab. 2012;10(2):464-9. https://doi.org/10.5812/ijem.3794.

  • 2.

    Fusaro M, D'Angelo A, Scalzo G, Gallieni M, Giannini S, Guglielmi G. Vertebral fractures in dialysis: Endocrinological disruption of the bone-kidney axis. J Endocrinol Invest. 2010;33(5):347-52. [PubMed ID: 20534970].

  • 3.

    Adami S. Bone health in diabetes: considerations for clinical management. Curr Med Res Opin. 2009;25(5):1057-72. [PubMed ID: 19292601]. https://doi.org/10.1185/03007990902801147.

  • 4.

    Kanis JA, Johansson H, Oden A, McCloskey EV. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone. 2010;47(4):729-35. [PubMed ID: 20601292]. https://doi.org/10.1016/j.bone.2010.06.009.

  • 5.

    Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther. 2008;12(3):157-70. https://doi.org/10.1007/BF03256280.

  • 6.

    Boonen S, Nicholson P. Assessment of femoral bone fragility and fracture risk by ultrasonic measurements at the calcaneus. Age Ageing. 1998;27(2):231-7. [PubMed ID: 16296685]. https://doi.org/10.1093/ageing/27.2.231.